本帖最后由 老马 于 2012-1-13 21:20 编辑
$ K0 w! K1 n$ |: n2 S* Y( h% @% V; V- c" H; N' b
爱必妥和阿瓦斯丁的比较
/ L/ C& d6 ~/ m+ i4 L5 m
/ u' \' C) }* P# K. phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) c; W+ s; O( I; i0 t- d. t
6 z. h) g) B; I% J% f
$ C: E+ W* m( c3 m- Ahttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/7 @$ J8 W) A5 ?% X; w) q
==================================================% E( b3 R2 K4 X; l/ l. J* Y! E- G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- e" x' m1 A0 s; p; q# MPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* ~# }: `+ K* G3 H2 M
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 _7 E+ \8 c4 ]+ S4 ]& F
|